Europe’s largest and most influential vaccine congress

- Qualify the investment trends of innovative funding versus traditional finance that are invigorating the vaccine market
- Focus on the strategic and competitive factors that are dictating the resurgence in vaccines across key stakeholders
- Evaluate the near, mid and long term business opportunities within vaccines and how to position your company to effectively exploit them
- Align your product portfolio capability with operational strategy; best position yourself as a future influence in the vaccine industry
- Develop relationships within the wider public, private and global health circles that will enable the development of future initiatives
- Four congress days and 13 exclusive streams giving you more choice than ever before

Sponsors and exhibitors

Organised by

www.lifescienceworld.com/2008/wvcl
**An industry moving in the right direction**

Over the last five years, the status of the vaccine industry has changed radically. Whilst it has been said that the pharmaceutical industry has slowed down over the period, dented by generics, restrictive healthcare policies in developed countries and something of a breakdown in terms of innovation, it is the vaccine field that remains a very prosperous field.

With a growth rate unheard of in other drug categories, given that it is expected to be a challenging year for the pharmaceutical industry, few other areas will see as many new product introductions and such public policy attention as vaccines in the coming months. It has created a tremendous opportunity for the development of vaccines on a global footing.

**Market maturity – adults now driving the growth of vaccines**

During much of the last century the success of vaccines were largely associated with the paediatric market and children. Whilst such markets remain a healthy priority worldwide and an important market, it is now adults who are fuelling the growth in vaccine products.

With a shift of market focus, vaccine stakeholders will need to identify clearly the key challenges and opportunities facing the vaccine industry. As important as ever will be the need to focus in on the ever changing dynamics from within product portfolio momentum, R&D pipeline potential, growth strategies and cost control. A focus that World Vaccine Congress Lyon will take in 2008.

**World Vaccine Congress Lyon is growing up too!**

Now celebrating its 10th birthday, World Vaccine Congress Lyon 2008 moves into double figures. Like a fine wine, World Vaccine Congress Lyon gets better with age as it continues to be the largest and longest established vaccine industry conference in Europe. In 2008 World Vaccine Congress Lyon celebrates 10 years of bringing together the World’s most compelling and influential scientific and business leaders to educate, conduct business and network.
Delivering the right people to the right place at the right time

Having successfully run World Vaccine Congress Lyon for the past 9 years, we have built each subsequent event on the strength of its speaker faculty and its attendees. There are very few vaccine industry conferences which can boast such a long and successful track record of delivering industry standard events. World Vaccine Congress Lyon is one of these.

Who will attend & why?

Vaccine manufacturers
- Focus on the evolving strategic factors that are shaping the adult and paediatric vaccine market and highlight the emerging regional and global opportunities on which stakeholders can maximise novel research and development programmes
- Explore external opportunities to help strengthen internal R&D pipelines that leverage off existing product lines and core process technologies. Tap into new technologies through collaboration with vaccine companies who hold innovative expertise

Biotech start-ups
- Identify traditional and innovative channels and sources of funding for early-stage investment during seed and series rounds. Make informed decisions on best practice in attracting desired investor interest and negotiating the all important deal
- Gain an understanding of the larger vaccine companies making early and mid-stage investments, and position your organisation with vaccine companies who are looking to leverage their expertise with a longer-term view of potential acquisition or partnerships

Biotechs
- Explore ways to enhance your research, product and technology development to match the most hotly demanded and promising areas of vaccine research. Align your portfolio capability with market requirements
- Understand the challenges of establishing and maintaining product development funnels and analyse ways of accelerating vaccine development whilst mitigating the inherent risks and costs

Contract service organisations
- Evaluate the near, mid and long term market opportunities for contract services in an industry increasingly using outsourced collaborations to drive advanced product development. Position your company to best exploit the burgeoning industry trend
- Hear from vaccine manufacturers and key biotech’s that require external capacity to execute their manufacturing and research strategies and align corporate capabilities to match the needs of individual clients

Well organised and topically very relevant with more focus on the vaccines business.
KV Balasubrananam, Managing Director, Indian Immunologicals

This meeting was very good. I enjoyed it very much. It addresses some important and pressing issues such as cancer vaccines, pandemic flu and adjuvants.
Lallan Giri, Vice President, Emergent Biosolutions

54% of the 2007 audience were vaccine manufacturers and biotechnology companies

72% of the total 2007 delegate profile were of Senior Director level or above. 16% were C-level executives

66% of the overall conference attendance in 2007 were of buy-side origin

67% of last years delegates attended from Europe, representing over 12 individual countries

20+ countries were represented in the 2007 audience creating a truly international event

68% of last years delegates registered as a means of exploiting senior level networking opportunities at the congress offering the most direct route to clients

150+ individual companies were represented in the 2007 World Vaccine Congress Lyon with multiple representation from key profiles with total attendance surpassing 215

66% of the 2007 congress audiences’ reason to attend was to hear from the industry’s leading practitioners
Plenary morning session

VACCINE POLICY, PIPELINES AND PROGRESS

08.00 Registration and coffee

09.00 Chairman’s opening remarks
Chris Colwell, Senior Adviser, McKenna, Long and Aldridge and Dr Stanley Eck, Chief Executive Officer, IOMAI

09.10 Challenges for European vaccine manufacturers and driving growth through innovation
- Premise of novel products injecting momentum into European vaccines market
- Addressing unmet medical needs both in adult and adolescent vaccine segments
- Challenges faced with respect to low profit margins, complex manufacturing and fragmented competition
- Advanced, high quality, cost-effective development and production to achieve future growth
Didier Hoch, President, sanofi pasteur MSD and President, European Vaccine Manufacturers

09.50 Supporting a renaissance in European vaccine industry innovation
- Vaccines market set to expand: new disease targets, broader age groups vaccinated
- What are the current opportunities and challenges of the European vaccine market?
- Aligning R&D efforts and commercial operations for market best fit
- Future expectations from the vaccine sector and Baxter’s influenza development
Denis Cavert, Vice President, Sales and Marketing, Europe, Baxter Vaccines

10.20 This is a revolutionary, exciting, quick and non-pressurised way to meet fellow conference delegates and industry peers in one sixty minute session. These brief meetings are the starting point for conversation and networking throughout the conference. This is where long lasting and fruitful relationships begin. Please make sure you bring lots of business cards!
- Meet…move on… meet….move on…. meet!
- Exchange business cards with fellow conference delegates, speakers and moderators
- The best networking session you’ve ever experienced!

11.20 Morning coffee

12.00 Vaccine perception and positioning in today’s biotech portfolios
- Adapting to new realities – the vision and flexibility towards advancing novel vaccine research
- Profiting from innovation – examining the inherent challenges and strategic opportunities
- Aligning innovative efforts and commercial operations
- Balancing risk and return across the vaccine market and corporate portfolio
Dr Clement Lewin, Vice President, Marketing, Policy and Strategy, Acambis

12.30 Strategies for novel vaccine development and introduction in Europe
- Development and harmonisation of regulations in key areas of concern for the vaccine industry
- Adapting and reacting to regulatory change around vaccines for industry
- Challenges to establishing a presence in the European vaccine market
- Aligning corporate strategies and commercial operations
Dr Frank Vandendriessche, Director, Regulatory Affairs Europe, Vaccines / Biologics, Merck Sharp & Dohme (Europe)

13.00 Lunch sponsored by Ovagen

ENGAGING VACCINES FOR COMPETITIVE ADVANTAGE

14.00 Session chairman
Chris Colwell, Senior Adviser, McKenna, Long and Aldridge and Dr Stanley Eck, Chief Executive Officer, IOMAI

14.05 Harnessing biotech innovation to improve the global health pipeline
- The role of biotech, the need for and the prospects of new and improved vaccines
- Adapting to new realities – the vision and flexibility towards investing in novel vaccine research
- Profiting from innovation – examining the inherent challenges and strategic opportunities
Gerd Zettlmeissl, Chief Executive Officer, Intercell

14.35 Developing new vaccines: responding to partnership opportunities
- Fresh strategic approaches to business development in vaccines
- What are the new prophylactic and therapeutic applications for which vaccines hold great promise?
- Balancing a vaccine development portfolio that targets major medical needs but minimises risk
Dr Allan Jarvis, Senior Vice President, Corporate Development, sanofi pasteur

15.05 R&D progress with recombinant vaccine development
- Discovery and development of innovative technologies in a rapidly changing vaccine environment
- Exploiting the industrial and commercial value of such technologies
- Combining discovery and development with cost-effective industrial production of vaccines
- Utilising technology platforms for internal research and development and in outlicensing deals
Franck Grimaud, Chief Executive Officer, Vivalis

15.30 Panel session: attractive opportunities promoting vaccine market development
- Forward looking developments with therapeutic vs. prophylactic and adult vs. paediatric
- Aligning R&D efforts and commercial operations with market opportunities
- Allocating resources that balances risk and return across a dynamic market place
Moderators:
Chris Colwell, Senior Adviser, McKenna, Long and Aldridge and Dr Stanley Eck, Chief Executive Officer, IOMAI

Panelists:
Didier Hoch, President, sanofi pasteur MSD and President, European Vaccine Manufacturers
Dr Allan Jarvis, Senior Vice President, Corporate Development, sanofi pasteur
Gerd Zettlmeissl, Chief Executive Officer, Intercell
Dr Michael Watson, Executive Vice President, Research and Development, Acambis

16.00 Afternoon tea
### GLOBAL HEALTH GOVERNANCE

**16.30** Session chairman  
Chris Colwell, Senior Adviser, McKenna, Long and Aldridge and Dr Stanley Eck, Chief Executive Officer, IOMAI

**16.35** Improving industry value proposition in pursuing global health initiatives  
- How can advances in vaccine innovation advance global health?  
- How can new impetus on R&D for developing markets be promoted amongst industry?  
- How are partnerships between public and private stakeholders driving progress?  
Dr Douglas Holtzman, Senior Program Officer, Infectious Diseases, Global Health Program, Bill & Melinda Gates Foundation

**17.00** Fostering incentives and innovation in vaccine financing  
- Evaluating current approaches to financing vaccine research and development; what is limiting progress?  
- Renewed impetus on investment in vaccines for diseases for developing countries  
- Incentives and innovative financing for developing new vaccines and global regulatory challenges  
- Investment: where is the money coming from? How to access it and is it sustainable?  
Dr Robert Hecht, Director, Health Policy, Results for Development Institute

**17.25** ‘Optimize’ – immunisation systems and technologies for tomorrow  
- New paradigms that address the needs of the coming decades – PATH and WHO catalysing a shared vision of the future logistics of health services  
- Using immunisation products and management practices at the country level and linkage with other primary health interventions, procurement, manufacturing, regulation, and global policies  
- State-of-the-art and innovative systems and practices for management, distribution, and use of vaccines and health products  
- Weaving together critical – and interrelated – paths to improve future logistics systems for immunisation and related health programs  
Michel Zaffran, Senior Adviser to Director of the Department of Immunisation, Vaccines and Biologicals, WHO and Senior Adviser and Project Optimize Director, WHO-PATH Collaboration

**17.50** Panel session: an evolving role of NGOs in support of global health and vaccine development  
- Public and NGO participation helping to promote and maintain industry involvement  
- Improving the value proposition for companies to pursue developing world products  
Moderators:  
Chris Colwell, Senior Adviser, McKenna, Long and Aldridge and Dr Stanley Eck, Chief Executive Officer, IOMAI

Panellists:  
Dr Douglas Holtzman, Senior Program Officer, Infectious Diseases, Global Health Program, Bill & Melinda Gates Foundation  
Dr Robert Hecht, Director, Health Policy, Results for Development Institute  
Michel Zaffran, Senior Adviser to Director of the Department of Immunisation, Vaccines and Biologicals, WHO and Senior Adviser and Project Optimize Director, WHO-PATH Collaboration

**18.20** Close of day one followed by 10th Anniversary Gala Dinner

### NOVEL VACCINE INTRODUCTION

**16.30** Session chairman  
Lance Gordon, President and Chief Executive Officer, ImmunoBiosciences Corporation

**16.35** HPV vaccine success and ongoing breakthroughs  
- Reviewing the clinical phase activities and commercialisation strategies for Gardasil™
- Exploring the pathway to approval and development with post licensure studies
- Addressing Gardasil™ vaccine introduction challenges  
Dr Randall Hyer, Senior Director, International Medical Affairs and Health Policy, Merck & Co.

**17.05** Case study: conjugate vaccines against N. meningitis ACWY and N. meningitis B late-stage vaccine development  
- What is the rationale behind the development of Meningococcal vaccines for both developed and developing markets  
- What is in the pipeline for Meningococcal conjugate vaccines development?  
- What alternative approaches for development of vaccines against Meningococcus B are currently being examined?  
Dr Alan Kimura, Senior Director, Meningococcal Vaccine Development, Novartis Vaccines & Diagnostics

**17.30** Case study: progress in the development of a Meningococcal Serogroup B vaccine  
- Furthering the development and commercialisation of a Meningococcal serogroup B vaccine  
- Vaccine development as both a stand-alone product and as a combination product together with glycoconjugate Pneumococcal and Meningococcal vaccines  
- Collaborative work on the development of a global multivalent Meningococcal B vaccine  
- Collaboration enhancing the development timeline and speeding up the licensing of the Meningococcal B vaccine  
Dr Ashoni Arora, Director, Vaccines Clinical Research, Wyeth-Lederle Vaccines

**17.55** Case study: Pneumococcal conjugate vaccines: what’s new?  
- The reasons behind the selection of a Pneumococcal conjugate vaccine  
- Illustrations over the selection of various strains  
- Clinical experience with the current strains  
- What needs to be developed for future conjugate vaccine development?  
Dr Bernard Fritzzell, Vice President of International Scientific and Clinical Affairs, Wyeth-Lederle Vaccines

**18.20** Close of day one followed by 10th Anniversary Gala Dinner

The Gala Dinner will be the evening highlight of World Vaccine Congress Lyon and will provide an evening of drinks and fine dining at one of Lyon’s famous gastronomic eateries, Brasserie Georges. Join the celebrations as World Vaccine Congress Lyon celebrates its 10th anniversary.
### Breakout stream 1

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00</td>
<td>Registration and coffee</td>
</tr>
<tr>
<td>09.00</td>
<td><strong>Session chairman</strong>&lt;br&gt;Dr Luc Hessel, Executive Director, Medical and Public Affairs, Europe, sanofi pasteur MSD, Member, Influenza Vaccine Supply International Task Force and Chair, Pandemic Flu Working Group, European Vaccine Manufacturers</td>
</tr>
<tr>
<td>09.10</td>
<td><strong>Coordinator</strong>&lt;br&gt;Dr Tony Colegate, Influenza Technical Affairs Manager, Novartis Vaccines &amp; Vaccines and Scientific Coordinator, Influenza Vaccine Supply International Task Force&lt;br&gt;&lt;br&gt;<strong>Coordinating vaccine development for pandemic influenza</strong>&lt;br&gt;• Recommendations on the strain selection for influenza virus vaccines&lt;br&gt;• Current vaccine manufacturer's views and perspectives on ongoing development</td>
</tr>
<tr>
<td>09.40</td>
<td>Developing cell culture derived pandemic vaccines&lt;br&gt;&lt;br&gt;• Using the Vero cell platform for influenza vaccines&lt;br&gt;• Immunogenicity and cross protection in animals&lt;br&gt;• Clinical trial strategy and first data in humans – safety plus pre-clinical and manufacturing processes&lt;br&gt;Dr Alexandra Loew-Baselli, Director, Clinical Development, Baxter AG</td>
</tr>
<tr>
<td>10.10</td>
<td>Integrating recombinant virus-like particles to exploit therapeutic influenza vaccines&lt;br&gt;&lt;br&gt;• Development of proprietary virus-like particle technology&lt;br&gt;• Immunologic and safety advantages of VLP vaccines&lt;br&gt;• Clinical development of a VLP vaccine against influenza&lt;br&gt;Dr Penny Heaton, Chief Medical Officer, Novavax</td>
</tr>
<tr>
<td>10.40</td>
<td>Morning coffee</td>
</tr>
<tr>
<td>11.10</td>
<td>Development of M2 influenza vaccine: targeting a highly conserved region of the influenza antigen&lt;br&gt;&lt;br&gt;• Concept of M2 influenza vaccine development&lt;br&gt;• Preclinical data demonstrating potent immune response&lt;br&gt;• Future of M2 influenza vaccines&lt;br&gt;Dr Martin Bachmann, Chief Scientific Officer, Cytos Biotechnology</td>
</tr>
<tr>
<td>11.40</td>
<td>Is there room for emerging companies in the pan flu space?&lt;br&gt;&lt;br&gt;• Advancing prospects for improved pandemic influenza vaccines – current review of FluGen&lt;br&gt;• Leveraging novel concepts out of university laboratories&lt;br&gt;• Small players find a viable space in the pan-flu world&lt;br&gt;Paul Radspinner, Chief Executive Officer, FluGen</td>
</tr>
<tr>
<td>12.10</td>
<td>How to supply flu vaccines in a pandemic situation&lt;br&gt;&lt;br&gt;• What are the steps in the pandemic vaccine supply chain?&lt;br&gt;• Government purchase of vaccines and technologies&lt;br&gt;Dr Luc Hessel, Executive Director, Medical and Public Affairs, Europe, sanofi pasteur MSD, Member, Influenza Vaccine Supply International Task Force and Chair, Pandemic Flu Working Group, European Vaccine Manufacturers</td>
</tr>
<tr>
<td>12.40</td>
<td>Lunch</td>
</tr>
</tbody>
</table>

### Breakout stream 2

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00</td>
<td>Registration and coffee</td>
</tr>
<tr>
<td>09.00</td>
<td><strong>Chairman's opening remarks</strong>&lt;br&gt;Dr Jeanne Novak, Chief Executive Officer, CBR International</td>
</tr>
<tr>
<td>09.05</td>
<td>Effective design of a clinical development programme for vaccines&lt;br&gt;&lt;br&gt;• An end point in mind, clinical trial design parameters&lt;br&gt;• Considerations for vaccine and therapeutic clinical trials&lt;br&gt;Dr Jeanne Novak, Chief Executive Officer, CBR International</td>
</tr>
<tr>
<td>09.30</td>
<td>Academic vaccine trial network in Finland for clinical evaluation of vaccines&lt;br&gt;&lt;br&gt;• Academic trial networks in broader clinical evaluation&lt;br&gt;• Pivotal studies roles in vaccine registration and licensing&lt;br&gt;Professor Timo Vesikari, Director of Vaccine Research Center, University of Tampere</td>
</tr>
<tr>
<td>09.55</td>
<td>Engaging e-learning and e-training activities for capacity building in vaccine trial sites&lt;br&gt;&lt;br&gt;• Online collaborative training programmes&lt;br&gt;• E-learning opportunities that support innovative face-to-face workshops in industrialised and developing countries&lt;br&gt;Dr Jean-Pierre Kraehenbuhl, Secretary, HSet Foundation, Senior Scientist, ISREC Foundation and emeritus Professor, University of Lausanne</td>
</tr>
<tr>
<td>10.20</td>
<td>Assessing immunogenicity and safety by high resolution monitoring of cell mediated immunity&lt;br&gt;&lt;br&gt;• Sensitive, validated GLP compliant ELISPOT assays&lt;br&gt;• Vital steps for successful immune monitoring strategies&lt;br&gt;Dr Thomas Kleen, Director, Business and Technology Development, Cellular Technology Limited</td>
</tr>
<tr>
<td>10.40</td>
<td>Morning coffee</td>
</tr>
</tbody>
</table>

### INFLUENZA PREPAREDNESS AND EVOLUTION

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.10</td>
<td>Session chairman&lt;br&gt;Dr Jeanne Novak, Chief Executive Officer, CBR International</td>
</tr>
<tr>
<td>11.15</td>
<td>Innovative technologies to improve economics and reduce contamination in vaccine processing&lt;br&gt;&lt;br&gt;• Flexible processing, cleaning and process validation&lt;br&gt;• Cell culture based processes using disposables&lt;br&gt;Robert Shaw, Director of Strategic Marketing, Program Director, Vaccines and Emerging Biotech, Millipore</td>
</tr>
<tr>
<td>11.45</td>
<td>Strategies for economic vaccine scale-up strategies&lt;br&gt;&lt;br&gt;• Preparing for sufficient vaccine production capacity during uneven periods of demand&lt;br&gt;• Novel technologies aiding scale-up in production&lt;br&gt;Dr Simon Hsu, Associate Director, Purification Development, Medimmune Vaccines</td>
</tr>
<tr>
<td>12.15</td>
<td>Panel session: technology solutions for critical vaccine production processes&lt;br&gt;&lt;br&gt;• Technology aiding the manufacture of vaccines&lt;br&gt;Moderator: Dr Jeanne Novak, Chief Executive Officer, CBR International&lt;br&gt;<strong>Panelists:</strong>&lt;br&gt;Dr Catarina Flyborg, Leader, Vaccine Initiative, GE Healthcare&lt;br&gt;Life Sciences&lt;br&gt;Marcel Thalen, Scientific Officer, SynCo Bio Partners&lt;br&gt;Dr Helen Fora, Vaccine Application Development Director, Pall Life Sciences</td>
</tr>
<tr>
<td>12.15</td>
<td>Lunch</td>
</tr>
</tbody>
</table>

### CLINICAL TRIALS AND TRIBULATIONS

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>13.00</td>
<td>Lunch</td>
</tr>
</tbody>
</table>
14.35 Primary endpoints for allergy vaccine studies
- Developing specific standardised vaccines and novel entrants to global allergy market
- Pollinex Quattro Grass phase III study, G301 safety and tolerability data
- Distinct technologies acting synergistically
  
  **Dr Raafat Fahim**, Chief Executive Officer, **Nabi Biopharmaceuticals**

15.05 Igniting the market with nicotine conjugate vaccine technology
- An innovative and proprietary investigational vaccine
- Demonstrating efficacy in supporting statistically significant and continuous abstinence rates
- Analysis data advancing ongoing clinical efforts
  
  **Dr Raafat Fahim**, Chief Executive Officer, **Nabi Biopharmaceuticals**

15.35 Novel immunotherapeutic vaccines for cardiovascular disease
- Incorporating a novel vaccine adjuvant, stimulating a much stronger immune response in models
- Phase 2a proof of concept study and current clinically meaningful reductions
  
  **Dr Ian Scoular**, Director of Business Development, **Protherics**

16.00 Afternoon tea

**VACCINE TECHNOLOGY INNOVATION**

16.30 Session chairman
**Graham Clarke**, Chief Executive Officer, **ImmunoBiology Ltd.**

16.35 DNA vaccines: generating strong, long-term immune responses
- DNA technology offering technical and economic advantages not feasible with conventional approaches
- Developing formulation and delivery technologies involving lipid molecules and synthetic polymers
  
  **Dr Alain Rolland**, Senior Vice President, Product Development, **Vical**

17.00 Anti-cytokine therapeutic vaccines
- Developing vaccine-induced polyclonal antibody therapies
- High-value drug discovery and development programs around well-validated cytokine targets
  
  **Guy-Charles Fanneau de La Horie**, Chief Executive Officer, **Neovacs**

17.25 Commercialisation of influenza virus-like particle vaccines using disposable manufacturing systems
- Manufacturing advantages of recombinant VLP vaccines in disposable systems
- Economics of influenza VLP manufacturing in disposable manufacturing systems
  
  **Dr James Robinson**, Vice President, Technical and Quality Operations, **Novavax**

17.50 Bacterial vectors for enhanced antigen delivery
- Bacterial vectors presenting an immunological advantage over virus based vaccines
- Listeria monocytogenes as a cancer vaccine vector
- Expanding clinical phase studies of listeria monocytogenes and current progress
  
  **Dr John Rothman**, Vice President, Clinical Development, **Advaxis**

18.15 Close of day two

**Breakout stream 2 continued**

**ADJUVANTS AND DELIVERY SYSTEMS**

14.00 Session chairman
**Dr Jeanne Novak**, Chief Executive Officer, **CBR International**

14.05 Mechanism of action of TLR-dependent and independent adjuvants
- Vaccine adjuvants enhancing immune response
- New approaches to study adjuvant mechanism of action
  
  **Dr Ennio de Gregorio**, Head of Immunology, Research Italy, **Novartis Vaccines & Diagnostics**

14.30 Novel adjuvant systems technology
- GSK’s history of adjuvant system development
- Proof of concept being carried out on the technologies
- GSK’s future adjuvanted vaccine technology pipeline
  
  **Dr Nathalie Garcon**, Vice President, Head of Research and North American R&D, **GlaxoSmithKline Biologicals**

14.55 TLR3 agonists for enhancing immune responses
- TLR3 agonist adjuvant for therapeutic and prophylactic vaccines
- Comparative pre-clinical data on Poly-ICL versus TLR9, TLR4, and TLR7 agonist adjuvants
  
  **Dr Peter Emtage**, Vice President, Research and Development, **Nventa Biopharmaceuticals**

15.20 Panel session: innovative vaccine delivery systems
- Technology and strategy transforming current vaccine delivery and impact on immunisation services
  
  **Moderator:**
  **Dr Jeanne Novak**, Chief Executive Officer, **CBR International**

  **Panellists:**
  **Dr Ulf Schröder**, Chief Scientific Officer, **Eurocine Vaccines**
  **Dr Charles Potter**, Chief Executive Officer, **Glide Pharma**
  **Dr Stanley Erick**, Chief Executive Officer, **IOMAI**

16.00 Afternoon tea

**VACCINE SAFETY EVALUATION**

16.30 Session chairman
**Dr Jeanne Novak**, Chief Executive Officer, **CBR International**

16.35 Vaccine manufacturing and quality: continuous process and product monitoring
- How can industry monitor vaccine production activities?
- Continuing to ensure the development and standard quality control of vaccines
  
  **Dr Lisa Plitnick**, Research Fellow, Biologics Release Testing and Immunotoxicology, **Merck & Co.**

17.05 Regulatory and clinical design issues in biosafety of vaccines
- Increased scrutiny on regulatory and safety design issues inherent in current procedures
- Design issues vs. feasibility
  
  **Dr Anne Fiquet**, Study Design and Evaluation Manager, Europe, **sanofi pasteur MSD**

17.35 Proactive vaccine safety and risk management
- Proactive risk management planning and activities – addressing a benefit-risk balance
- Outlining structures for safety specification, pharmacovigilance and risk minimisation planning
  
  **Dr Adrian Dana**, Senior Director, **CRMSS, Merck Research Laboratories**

18.05 Close of day two
12.25 Validation considerations of early stage biotech ventures – what are investors looking for?

- What is most important method of investors considering investment?
- What criteria biotech investors use to evaluate and fund investment-grade projects? Price vs. value
- What are the crucial factors to VCs when shaping their economic vaccine winners and losers
- License deals: valuation for structuring and comparing term sheets

Dr Boris Bogdan, Partner, Avance

12.55 Lunch

14.15 Aligning vaccine investment with strategic biotech opportunities

- Securing equity in promising emerging companies at an early and earlier stage. When to get involved
- Assessing risks as a potential investee: highlighting the key watchwords for investment
- Investing in companies whose technologies or products are closely aligned with investees goals

Michelle Dees, Director, Innovation Fund, International AIDS Vaccine Initiative

PARTNERSHIPS AND IP MANAGEMENT

14.45 Vaccine partnerships and intellectual property management

- When does IP management become a critical stage for commercialisation and investment?
- Challenges impacting the vaccine IP environment through private investment
- What does it mean to both the investor and investee when engaging in partnerships?

Dr Elizabeth Haanes, Director, Sterne, Kessler, Goldstein & Fox

15.15 Afternoon tea

FUTURE INVESTMENT OUTLOOK

15.45 Looking for leverage in the vaccine industry

- The comparative advantages for further investment in vaccines. Where is the attraction?
- Where will investors be placing future bets?
- What can be learned from previous successes and failures?

Francesco de Rubertis, Partner, Life Science Practice, Index Ventures

16.15 Panel session: regional comparisons over venture investing in vaccines

- How are regions shaping up in terms of vaccine investment opportunities?
- What are the types of investments that are developing within the vaccine space i.e. specific products, platform technologies, key enablers and royalty rights?
- What are the inherent differences when investing domestically and overseas?

Moderator: Lance Gordon, President and Chief Executive Officer, ImmunoBiologics Corporation

Panelists:
- Robert Paull, Managing General Partner, Lux Capital Management
- Dr Rafaèle Tordjman, Partner, Sofinnova Partners
- Francesco de Rubertis, Partner, Life Science Practice, Index Ventures

17.00 Close of pre-congress day followed by networking drinks reception
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00</td>
<td>Registration and coffee</td>
<td></td>
</tr>
<tr>
<td>09.00</td>
<td>Chairman’s opening remarks</td>
<td>Prof. Angus Dalgleish, Foundation Chair in Clinical Oncology, St. George’s Hospital Medical School and Research Director, OnyxVax</td>
</tr>
<tr>
<td>09.10</td>
<td>Optimising prevention with the next generation Hepatitis B vaccine</td>
<td>Dr Zbigniew Janowicz, Chief Executive Officer, Dynavax Europe</td>
</tr>
<tr>
<td>09.40</td>
<td>Targeting the innate immunity for immunotherapeutic vaccines in oncology and infectious diseases</td>
<td>Dr Patrick Squiban, Chief Medical Officer, Innate-Pharma</td>
</tr>
<tr>
<td>10.10</td>
<td>Advancing autologous, hapten-modified melanoma vaccines</td>
<td>Dr David Berd, Chief Medical Officer, AVAX Technologies</td>
</tr>
<tr>
<td>10.40</td>
<td>Morning coffee</td>
<td></td>
</tr>
</tbody>
</table>
| 11.10  | Commercialisation: immediate short-term, vast long-term potential of OncoVAX® | Demonstrating efficacy in stage II colon cancer patients  
Reviewing successful Phase IIIa clinical trial data pertaining to final translational development  
Upcoming pivotal Phase IIIb clinical trial under Special Protocol Assessment (SPA)  
Dr Michael Hanna, Jr., Chief Executive Officer, Vaccinogen |
| 11.40  | Panel session: clinical trial design considerations for therapeutic cancer vaccines | How should clinical trials be designed so that the endpoints reflect the actions of the vaccines?  
Strategies for clinical trials and immune assessment  
Cancer vaccine regulatory challenges in clinical trials – hope for the future  
Moderator: Prof. Angus Dalgleish, Foundation Chair in Clinical Oncology, St. George’s Hospital Medical School and Research Director, OnyxVax  
Panellists:  
Dr Zbigniew Janowicz, Chief Executive Officer, Dynavax Europe  
Dr Patrick Squiban, Chief Medical Officer, Innate-Pharma  
Dr David Berd, Chief Medical Officer, AVAX Technologies  
Dr Michael Hanna, Jr., Chief Executive Officer, Vaccinogen |
| 12.10  | Lunch                                                                         |                                                                                                                                             |
| 13.10  | Colorectal cancer and the peptide-based therapeutic vaccine IMA910            | Dr Jean-Yves Bonnefoy, Vice President Research and Development, Transgene  
Optimising prevention with the next generation Hepatitis B vaccine  
Aim of Phase 1/2 trials to assess the preliminary safety and first evidence of efficacy  
Discovery and pre-clinical development that led to IMA910  
Dr Niels Emmerich, Chief Operating Officer, Immatics Biotechnologies |
| 13.40  | Therapeutic vaccines and immunotherapeutic products for non-small cell lung cancer | Assessing the efficacy of TG4010 (MVA-MUC1-IL2) in combination with cisplatin and gemcitabine  
Preliminary results of Phase IIb trial with TG4010 in non-small cell lung cancer  
On-going centralised review process of trials and combination therapy  
Dr Jean-Yves Bonnefoy, Vice President Research and Development, Transgene |
| 14.10  | Recombinant vaccines for the immunotherapy of breast and prostate cancer     | Recombinant MVA-BN® - a backbone for cancer vaccines  
Preclinical activity and Phase II trial safety, immunogenicity and activity data  
Clinical trial strategies leading to BLA  
Dr Reiner Laus, Chief Executive Officer, BN ImmunoTherapeutics |
| 14.40  | Panel session: challenges faced by cancer vaccine manufacturers              |    
Difficulties faced by manufacturers of cancer vaccines  
Development questions to be considered before a developer pursues a particular vaccination strategy  
Key adjuvants now in development for cancer vaccines, and which agent is showing the greatest promise  
Moderator: Prof. Angus Dalgleish, Foundation Chair in Clinical Oncology, St. George’s Hospital Medical School and Research Director, OnyxVax  
Panellists:  
Dr Niels Emmerich, Chief Operating Officer, Immatics Biotechnologies  
Dr Jean-Yves Bonnefoy, Vice President Research and Development, Transgene  
Dr Reiner Laus, Chief Executive Officer, BN ImmunoTherapeutics |
| 15.10  | Afternoon tea                                                                 |                                                                                                                                             |
| 15.30  | Cancer vaccines: do we really need antigens in the formulation?              | A fully synthetic adjuvant which stimulates both a strong T cell and B cell immune response against antigens  
Anti-microbial peptide, KLK and an immuno stimulatory oligodeoxynucleotide, ODN1  
IC31® unique broad mechanism of action  
Professor Alexander von Gabain, Chief Scientific Officer, Intercell |
| 16.00  | Cancer vaccines: do we really need antigens in the formulation?              | Systemic activation of antigen presenting cells during the course of first line chemotherapy in advanced cancer  
The clinical trials: high dose CpG, anti-CD40 mAb and LAG-3 (IMP321)  
First results with IMP321 given s.c. during first line paclitaxel therapy in metastatic breast cancer  
Dr Frédéric Triebel, Scientific and Medical Director, Immutep |
| 16.30  | Close of post-congress briefing                                              |                                                                                                                                             |
Enjoy a truly complete conference experience

At World Vaccine Congress Lyon we take our role of providing you with an informative and enjoyable event very seriously. We see our conferences as much more than a four day event, but a whole experience taking into account everything from speakers and chairmen, to the content of the presentations, the social and business networking and the follow up to great relationships made at the event. Here are a few examples of what makes us different:

Introducing you to your peers and your suppliers. ‘Contact’ is Terrapinn’s unique online introductory service. It’s a simple system designed with event attendees in mind, giving you the list of attendees and the option to email them to arrange meetings with the meetings calendar and begin networking prior to the event. It is available to all event attendees. Don’t leave meeting the best event attendees to chance. Contact them before the event, contact them after the event. Stay in contact!

Our online system also allows you to download the presentations after the event, ensuring you only receive the information you want.

Speed networking: you’ll be surprised at how much you’ll enjoy this. It’s designed to quickly introduce you to a large number of new contacts in one powerful 60 minute session. These meetings initiate contacts that often last well beyond the four days of the conference and often blossom into fruitful and lasting business relationships. Make sure you bring plenty of business cards!

The conference programme includes several panel sessions. These are ‘talk show’ style sessions creating an interactive environment rather than a lecture. The panellists are chosen for their views and lively debate is encouraged. This is your chance to interact and put your questions to the panel.

World Vaccine Congress Lyon features a pre-congress evening drinks reception on the 6th October. This informal drinks reception gives you a chance to unwind at the end of the pre-congress briefing day or simply register early for the start of the main conference and enjoy an early networking opportunity to mix with your peers, sponsors and exhibitors. Take this chance to further develop relationships with the congress attendees and strengthen business contacts for the conference ahead.

To celebrate 10 years of World Vaccine Congress Lyon we will be hosting a Gala Dinner at the renowned Brasserie Georges, a monument of Lyonnaise gastronomy since 1836, the oldest in Lyon, designed in art deco style with majestic ceilings and lustrous frescos. In addition to helping celebrate World Vaccine Congress Lyon reach this milestone you will also maximise your networking opportunities from the congress and experience a truly wonderful gastronomic experience.

Venue

Between the Rhone and the Tête d’Or Park, the Palais des Congrès de Lyon proudly shows its original and elegant silhouette. Flooded with light, transparent and functional, it is inscribed in the new generation of event environments and fully satisfies the expectations of users in terms of service. The innovative ideas behind the conference centre can be seen in its ergonomic design, aesthetic treatment, modular use of space and sophisticated technological facilities. The Hilton Hotel, attached to the Palais des Congrès de Lyon is genuine five star comfort, set between the banks of the Rhône River and the Tête d’Or Park. www.palais-des-congres.com

The year’s most expansive vaccine congress is waiting to welcome you. Book before 25 July and save up to €573! Fax back the registration page to +44 (0)20 7242 2320 or register online at www.lifescienceworld.com/2008/wvcl
Immunise your business from market uncertainties!

Give your business the shot in the arm it deserves – it’s the event where the who’s who of the vaccine community overcome their challenges.

World Vaccine Congress Lyon is the number one platform for world class vendors and solution providers, like you, to showcase your products and expertise to the biggest ever targeted vaccine audience. This is your chance to be part of the most cost effective marketing solution in the vaccine industry. Reduce the time taken to meet new customers, reduce the costs of advertising and maximise the return on your investment.

Your direct route to market

World Vaccine Congress Lyon is the number one platform for world class vendors and solution providers, like you, to showcase your products and expertise to the biggest ever targeted vaccine audience. This is your chance to be part of the most cost effective marketing solution in the vaccine industry. Reduce the time taken to meet new customers, reduce the costs of advertising and maximise the return on your investment.

Who should sponsor and exhibit

The World Vaccine Congress offers a total marketing and business development solution to companies looking to position themselves at the forefront of the vaccine industry, generate more leads and make more sales. If this is you, and you fall into one of the categories below, then the World Vaccine Congress Lyon is your chance to get ahead of your competitors:

• CROs
• CMOs
• Equipment providers
• Delivery technology manufacturers
• Vaccine technology platform providers
• Regional development agencies
• Biotechs
• Consultants
• Cold chain and logistics
• Law firms
• Venture capitalists

Delivering real results

No other event can give you exclusive access to senior decision makers from key vaccine, pharmaceutical, biotech companies and government bodies. Sponsoring or exhibiting at the World Vaccine Congress Lyon is an exceptional opportunity to be part of a 24/7 targeted marketing campaign that not only guarantees a quality audience but also keeps your target markets informed about you.

Focus your marketing spend

The global vaccine industry has been experiencing something of a renaissance in the last five years and this is no more evident than in the huge interest that is already being generated in the World Vaccine Congress Lyon. Now is the time to focus your global operations and use the World Vaccine Congress Lyon to your full advantage.

Come and network with the industry leaders, generate leads, sell your services, increase your company’s profile or just show the world that you’re still at the front of the fleet.

• Reduce the time taken to meet global customers – they’ll all be in Lyon in October
• Reduce the costs of advertising – take advantage of our multi-channelled marketing solutions
• Maximise return on your investment – meet your clients in Lyon and do business

Organisation by industry type

Delegate by job title

Response form

Fax Back to +44 (0)20 7242 1508

☐ Yes! I am interested in sponsorship opportunities. Please contact me immediately.

☐ Yes! I am interested in exhibiting. Please contact me immediately.

Name: ................................................................. Job title: .................................................................

Company: ........................................................................................................................................

Address: ...........................................................................................................................................

Tel: ................................................................................................ Fax: ......................................................... Email: .................................................................

Code: 14/1353
Registration form

**Corporate booking prices cannot be used in conjunction with any other promotional prices.**

### 5 easy ways to register

- **Phone:** +44 (0)20 7242 2324
- **Fax:** +44 (0)20 7242 2320
- **Online:** www.lifescienceworld.com/2008/wvcl
- **Email:** sarah.pegden@terrapinn.com
- **Post:** Terrapinn Ltd, Wren House, 43 Hatton Garden, London, EC1N 8EL, UK

<table>
<thead>
<tr>
<th>Please register me for:</th>
<th>Package</th>
<th>Dates</th>
<th>Received before 25 July 2008</th>
<th>Received after 25 July and before 22 August 2008</th>
<th>Received after 22 August 2008</th>
</tr>
</thead>
<tbody>
<tr>
<td>VIP Pass – all 4 days and gala dinner</td>
<td>6 – 9 October 2008</td>
<td>€4,315.50 + VAT €545.94 = €5,161.44</td>
<td>SAVE €1,712.07</td>
<td>€4,315.50 + VAT €982.83 = €5,498.08</td>
<td>SAVE €97.14</td>
</tr>
<tr>
<td>2 day conference, pre-conference briefing and gala dinner</td>
<td>6 – 8 October 2008</td>
<td>€3,415.50 + VAT €669.44 = €4,084.94</td>
<td>SAVE €453.88</td>
<td>€3,625.26 + VAT €706.63 = €4,311.88</td>
<td>SAVE €228.94</td>
</tr>
<tr>
<td>2 day conference, post-conference briefing and gala dinner</td>
<td>7 – 9 October 2008</td>
<td>€3,415.50 + VAT €669.44 = €4,084.94</td>
<td>SAVE €453.88</td>
<td>€3,625.26 + VAT €706.63 = €4,311.88</td>
<td>SAVE €228.94</td>
</tr>
<tr>
<td>2 day conference and gala dinner</td>
<td>6 – 7 October 2008</td>
<td>€2,497.50 + VAT €489.51 = €3,316.18</td>
<td>SAVE €453.88</td>
<td>€2,636.25 + VAT €516.71 = €3,152.96</td>
<td>SAVE €228.94</td>
</tr>
<tr>
<td>Pre-conference briefing</td>
<td>6 October 2008</td>
<td>£1,075.50 + VAT £210.80 = £1,386.30</td>
<td>SAVE €142.92</td>
<td>€1,135.50 + VAT €222.51 = €1,357.76</td>
<td>SAVE €17.16</td>
</tr>
<tr>
<td>Post-conference briefing</td>
<td>9 October 2008</td>
<td>£1,075.50 + VAT £210.80 = £1,386.30</td>
<td>SAVE €142.92</td>
<td>€1,135.50 + VAT €222.51 = €1,357.76</td>
<td>SAVE €17.16</td>
</tr>
</tbody>
</table>

* 50% discount for government, academia and non profit organisations

### Corporate groups. Yes, I want to send the team and save even more.

<table>
<thead>
<tr>
<th>Delegates</th>
<th>Normal Price</th>
<th>Group Price</th>
<th>Total savings</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 VIP pass</td>
<td>£14,385.50 + VAT £2,819.46 = £17,204.96</td>
<td>£12,946.50 + VAT £2,537.51 = £15,484.01</td>
<td>SAVE £1,720.45</td>
</tr>
<tr>
<td>6 VIP pass</td>
<td>£28,770.92 + VAT £5,638.92 = £34,308.84</td>
<td>£23,016.94 + VAT £4,511.14 = £27,528.08</td>
<td>SAVE £6,780.76</td>
</tr>
<tr>
<td>8 VIP pass</td>
<td>£38,960.56 + VAT £7,518.56 = £46,479.12</td>
<td>£33,157.95 + VAT £6,527.14 = £39,685.09</td>
<td>SAVE £6,780.76</td>
</tr>
</tbody>
</table>

### Attendee details

<table>
<thead>
<tr>
<th>Mr/Mrs/Ms</th>
<th>Full name</th>
<th>Job title</th>
<th>Telephone</th>
<th>Email</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

If you are booking more delegates, please attach a separate sheet with details of all attendees. Alternatively call +44 (0)20 7242 2324.

### Company details

Signatory must be authorised to sign on behalf of contracting organisation.

- **Name:**
- **Job title:**
- **Authorising signature:**
- **Email:**
- **Organisation name:**
- **Industry:**
- **Address:**
- **Postcode:**
- **Country:**
- **Tel:**
- **Fax:**

### Method of payment

Payment terms are 14 days. The conference registration pack will be sent to you once payment has been received:

- **Bank Transfer**
- **Crossed cheque payable to Terrapinn Ltd**
- **Diners Club**
- **Visa**
- **American Express**
- **Mastercard**

- **Card number:**
- **Card holder’s signature:**
- **Expiry date:**
- **Security code:**


### For official use only

- **Received:**
- **Date:**
- **Code:**
- **ABCD EFGHIJKLMNOPQRSTUVWXYZ**

### Venue and hotel accommodation

**Venue:** Palais des Congrès de Lyon

50, quai Charles de Gaulle, 69603 Lyon Cedex 06, France

Tel: +33 4 72 28 26 26  Fax: +33 4 72 28 26 27  www.palais-des-congres.com

**Hotel accommodation:** The conference fee does not include accommodation. Terrapinn has obtained specially discounted rates for all attendees. A hotel booking form will be sent to all registered attendees. Please book your accommodation early to avoid disappointment.

### Data Protection

Terrapinn (or its agents) may contact you by mail, phone or email about products and services offered by Terrapinn and its group companies, which Terrapinn believes may be of interest to you, or about relevant products and services offered by reputable third parties. Terrapinn may also disclose your contact details to such third parties to enable them to contact you directly. Certain entities to which Terrapinn discloses your contact details are located in territories overseas which have fewer legal safeguards to protect personal data. By returning this form to us, you agree to our processing of your personal information in this way. Please tick the appropriate box if you do not wish to receive such information from:

- **the Terrapinn group;**
- **or reputable third parties.**

### Cancellation

1. Should you be unable to attend, a substitute delegate is welcome at no extra charge.
2. Should you wish to cancel completely a charge of 50% of the registration fee, plus £150 (+ VAT) administrative charge will be made for cancellations received in writing at least 30 days prior to the conference start date.
3. Alternatively, you may choose a credit note for the full value of the registration fee valid for 1 year, which may be put towards another Terrapinn event.
4. The company regrets that no cancellations will be accepted within 30 days of the conference start date. Prepayments will not be refunded and invoiced sums will be payable in full, except in cases where it has been possible to mitigate loss.
5. Course documentation will, however, be made available to the delegate. Terrapinn reserves the right to alter the programme without notice.

### Insert your voucher code

- **Code:**
- **ABCD EFGHIJKLMNOPQRSTUVWXYZ**

### Offer details

- **Normal Price**
- **Group Price**
- **Total savings**

- **5 easy ways to register**
- **Phone:** +44 (0)20 7242 2324
- **Fax:** +44 (0)20 7242 2320
- **Online:** www.lifescienceworld.com/2008/wvcl
- **Email:** sarah.pegden@terrapinn.com
- **Post:** Terrapinn Ltd, Wren House, 43 Hatton Garden, London, EC1N 8EL, UK